



Northern Health December Formulary Update

New Formulary Medications:

- a. lipid emulsion (CLINOLEIC). Note: BC P&T determined that there are no clinically meaningful differences between the lipid emulsion brands on market (e.g. SMOF, INTRALIPID); therefore, lipid emulsions will be generically listed on formulary and it will be up to each health authority to determine which products to carry.
- b. 3-in-1 TPN products: all 3-in-1 products will be added to formulary as line extensions since both the macronutrient 2-in-1 products and the lipid emulsions already exist separately on formulary.

New Formulary Restricted Medications:

- a. infliximab (biosimilar RENFLEXIS and INFLECTRA): restricted to severe immune-mediated enterocolitis associated with check-point inhibitors (e.g. ipilimumab) unresponsive to steroid therapy.
- b. alitretinoin (TOCTINO) capsule: restricted to indications outlined in the BC Cancer Benefit Drug List AND patients who are registered with BC Cancer.

Excluded Medications:

- a. abacavir-lamivudine-zidovudine (TRIZIVIR) oral tablet
- b. infliximab (REMICADE): this brand is now removed from formulary and has been replaced by the biosimilar brands as noted above
- c. travoprost-timolol (DUOTRAV PQ) ophthalmic drops

December 24, 2021 For the information of physicians, nurses, and pharmacists. PLEASE POST	Formulary Changes	√	For further information contact: <i>Jessica Granberg *or* Ryan Doerksen</i> Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		